Implantable Drug-Eluting Devices Market - Global Industry Analysis

Implantable Drug-Eluting Devices Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2026

Category: Pharmaceutical Report Format : PDF Report Code: ZMR-6254 Status : Upcoming

Description

Global Implantable Drug-Eluting Devices Market: Overview

Implantable drug-eluting devices assist site-specific drug administration. It also helps in minimizing doses of drugs to lower the potential side effects. Such devices offer sustained release of a therapeutic agent. These devices gain a competitive edge over traditional parental and oral dosage forms due to the sustained and site-specific release action of these implantable devices. Also, the treatment schedule associated with these drug-eluting devices is less burdensome than injections or pills.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Global Implantable Drug-Eluting Devices Market: Growth Factors

One of the major factors driving the growth of the global implantable drug-eluting devices market is the growing incidences of chronic diseases like diabetes and cancer all across the globe. Such diseases have created an urgent need for efficient medication delivery and thus there is a significant spike in the demand for such implantable drug-eluting devices. The growing initiative from government authorities all across the globe to ensure high patient safety standards is another key factor driving the growth of the global market vigorously during the forecast period. Moreover, the growing awareness regarding the availability of safe and high-quality products among patients also boosts the demand for implantable drug delivery devices in the market globally. The growing preferences for drug-device combination products due to their high efficacy are also fuelling the demand for such drug-eluting devices all across the globe. The growing popularity of microscale implantable devices along with multiple applications like diagnosis and therapy is also a major factor attributing to the growth of the global implantable drug-eluting devices market during the forecast period. Such devices also help in monitoring the various bodily functions and facilitate therapy & imaging along with stimulating tissues in the movement disorders. The emergence of implantable drug-eluting devices has helped in targeted therapy along with the controlled medication delivery.

Global Implantable Drug-Eluting Devices Market: Segmentation

The global implantable drug-eluting devices market can be segmented into application, technology, type, product, and region.

By application, the market can be segmented into autoimmune diseases, oncology, diabetes, cardiovascular, ophthalmology, contraception, and others. The cardiovascular application segment accounts for the largest share in the global market as a large pool of the population is suffering from cardiovascular incidences. Also, the high adoption rate of drug-eluting stent in the process of treatment for the cardiovascular condition is fuelling the growth of the segment.

By technology, the global implantable drug-eluting devices market can be segmented into magnetic, cosmetic, diffusion, and others. The diffusion segment holds the largest share in the global market due to its wide utilization in the treatment process of chronic diseases that require intensive therapy administration.

By type, the market can be segmented into non-biodegradable and biodegradable. The non-biodegradable devices segment holds hegemony over the other. Also, the biodegradable segment is anticipated to witness exponential growth due to the various associated advantages like positive outcomes, high patient compliance, and greater acceptance.

By product, the market can be segmented into infusion pumps, intraocular stents, bioabsorbable stents, drug-eluting stents, brachytherapy seeds, spinal implants, contraceptive implants, and others. The drug-eluting stents segment dominates the global implantable drug-eluting devices market due to the growing adoption of non-biodegradable implants in pain management, cancer treatment, contraception, and hormone regulation.

Global Implantable Drug-Eluting Devices Market: Regional analysis

North America holds the largest share in the global implantable drug-eluting devices market due to the ongoing development activities in the region. Also, the growing initiatives by the government authorities to lower the growing burden of disease in the region are further boosting the growth of the regional market.

Asia Pacific is anticipated to witness huge growth during the forecast period due to the growing investments from government authorities as well as prominent market players to strengthen the healthcare infrastructure in the region. Also, the growing regulatory policies to ensure your high safety standard and healthcare quality are also fuelling the growth of the regional market.

Global Implantable Drug-Eluting Devices Market: Competitive Players

Some of the significant players in the global implantable drug-eluting devices market are Abbott, JVS, Elekta, Ziegler, Eckert, Arrow International, Bayer AG, Varian Medical Systems, Inc., Stryker, Bausch and Lomb Incorporated, Merck & Co., Inc., Allergan, and Boston Scientific Corporation.

Global Implantable Drug-Eluting Devices Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

What Reports Provides

  • Full in-depth analysis of the parent market
  • Important changes in market dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets
  • Testimonials to companies in order to fortify their foothold in the market.

Table Of Content


Frequently Asked Questions

One of the major factors driving the growth of the global market is the growing incidences of chronic diseases like diabetes and cancer all across the globe. Such diseases have created an urgent need for efficient medication delivery and thus there is a significant spike in the demand for such implantable drug-eluting devices.

Some of the significant players in the global implantable drug-eluting devices market are Abbott, JVS, Elekta, Ziegler, Eckert, Arrow International, Bayer AG, Varian Medical Systems, Inc., Stryker, Bausch and Lomb Incorporated, Merck & Co., Inc., Allergan, and Boston Scientific Corporation.

 

North America holds the largest share in the global market due to the ongoing development activities in the region. Also, the growing initiatives by the government authorities to lower the growing burden of disease in the region are further boosting the growth of the regional market.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social